Sajith Wickramasekara

Co-founder and CEO, Benchling
· tracked since Jan 2026
Calls
1
Win Rate
100.0%
return
+27.7%
Calls 1 1 Posts tracked · 0.0/day
Calls
7d 0
30d 0
90d 0
Win Rate 100% Long 1 Short 0
Win Rate
7d 100%
30d 0%
90d 100%
Average Return +27.7% Long Return +27.7% Short Return -
Average Return
7d +1.2%
30d -0.5%
90d +6.7%
Visual Insights Log in to see more
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
XBI 1ST SPDR S&P... SPDR S&P Biotech ETF
Long
Jan 13
$123.78
+27.7%
Biotech sentiment and M&A recovering
Biotech sentiment is improving: XBI has been trading well, M&A has returned money to investors, and tariff and most-favored-nation drug-pricing concerns have settled for now. Eli Lilly becoming a trillion-dollar pharma company also raises ambitions for the sector, even though drug discovery remains a long, difficult process.
Thematic ETFs
YOUTUBE
Showing 1 of 1 calls · sorted by mentions

Sajith Wickramasekara has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: XBI.

Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology